Send to

Choose Destination
Expert Rev Neurother. 2014 Jan;14(1):5-8. doi: 10.1586/14737175.2014.864556. Epub 2013 Dec 2.

Pramipexole augmentation in treatment-resistant major depressive disorder.

Author information

Department of Psychiatry, The Catholic University of Korea College of Medicine, Seoul, South Korea and.


Evaluation of: Cusin C, Iovieno N, Iosifescu DV et al. A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder. J. Clin. Psychiatry 74(7), e636-e641 (2013). To overcome limited efficacy in antidepressants, clinicians may choose augmentation, switching to a different antidepressant, or a combination of different antidepressant drugs based on the individual patient's clinical circumstances. Among such options for difficult-to-treat major depressive disorder (MDD) patients, augmentation therapy with atypical antipsychotics, psychostimulants, dopamine agonists, serotonin 1A partial agonists, lithium, and thyroid hormones are commonly used in clinical practice. In fact, augmentation therapy has some clinical merits and is more convenient than switching medications and combination approaches for treating MDD. One such augmentation agent, pramipexole has been proposed, and has been implicated in the development and treatment of MDD. Recently, randomized controlled trials with pramipexole augmentation have been conducted and have demonstrated that pramipexole is a safe and potentially efficacious augmentation strategy. This article will discuss currently available clinical trial data and the potential role of pramipexole in MDD treatment, including clinical significance, limitations, and future research directions.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center